Enzymatic Conjugation of Polypeptides

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes improved methods for the site-specific enzymatic conjugation of drugs or other functional groups to antibodies (immunoglobulins). By optimizing both the structure of the antibody (through specific mutations and glycosylation control) and the design of the linking reagent, the method enables homogenous, efficient, and almost complete attachment of even large, hydrophobic, or charged payloads (such as cytotoxic drugs) to antibodies using transglutaminase enzymes. The technology allows for improved antibody-drug conjugate (ADC) production with well-defined drug-to-antibody ratios and high product stability.

Use CasesContent extracted from patent full text and abstract with AI.

• Development of antibody-drug conjugates (ADCs) for targeted cancer therapies.
• Manufacture of diagnostic antibodies labeled with imaging agents or other markers for disease detection.
• Preparation of homogeneous antibody conjugates with tailored pharmacokinetics for different therapeutic applications.
• Production of site-specifically modified antibodies for research or biotechnological applications requiring high uniformity and stability.
• Rapid screening of various drug-linker-antibody combinations to optimize therapeutic efficacy.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables efficient and nearly complete conjugation of large, hydrophobic, or charged drugs to antibodies, overcoming limitations of existing methods.
• Produces highly uniform and stable antibody conjugates with predictable drug-to-antibody ratios, improving therapeutic index and reducing side effects.
• Reduces use of toxic organic solvents and reaction excesses, lowering production costs and improving safety.
• Supports both single-step and multi-step conjugation strategies, increasing flexibility in drug or label attachment.
• Improves product stability and reduces aggregation, resulting in better storage profiles and longer shelf life.
• Facilitates the development of a new generation of ADCs with expanded therapeutic range and more controlled properties.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present application relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.